Improving the efficacy of photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model

Theranostics

Volumn 3, Issue 6, 2013, Pages 357-365

  Nakajima, Takahito ^a   Sano, Kohei ^a   Choyke, Peter L ^a   Kobayashi, Hisataka ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Binding site barrier; Cocktail; Micro distribution; Monoclonal antibody; Photoimmunotherapy

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BASILIXIMAB; BASILIXIMAB PHTHALOCYANINE CONJUGATE; CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; PANITUMUMAB; PANITUMUMAB BASILIXIMAB PHTHALOCYANINE CONJUGATE; PANITUMUMAB PHTHALOCYANINE CONJUGATE; PHTHALOCYANINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; CELL DEATH; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; HISTOLOGY; IN VIVO STUDY; INFRARED RADIATION; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PERMEABILITY BARRIER; PHOTOIMMUNOTHERAPY; PHOTOTHERAPY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RADIATION EXPOSURE; TARGET CELL; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT;

BINDING SITE BARRIER; COCKTAIL; MICRO-DISTRIBUTION; MONOCLONAL ANTIBODY; PHOTOIMMUNOTHERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARBOCYANINES; CELL DEATH; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; INFRARED RAYS; MICE; NEOPLASMS; ORGANOPHOSPHORUS COMPOUNDS; PHOTOTHERAPY; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 84883194936     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.5908     Document Type: Article

References (29)

1. Waldmann TA. Immunotherapy: past, present and future. Nat Med. 2003; 9:269-77.
2. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol. 2005; 23:1073-8.
3. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Na Nat Rev Cancer. 2006; 6:559-65.
4. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal J-F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006; 24:823-34.
5. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988; 48:7022-32.
6. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 2003;63: 1288-96.
7. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008; 60:1421-34.
8. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res. 1989; 49:5656-63.
9. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med. 1990; 31:1191-8.
10. van Osdol W, Fujimori K, Weinstein JN. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier". Cancer Res. 1991; 51:4776-84.
11. Juweid M, Neumann R, Paik C, Perez-bacete MJ, Sato J, Osdol WV, et al. Micropharmacology of Monoclonal Antibodies in Solid Tumors : Direct Experimental Evidence for a Binding Site Barrier Micropharmacology of Monoclonal Antibodies in Solid Tumors : Direct Experimental Evidence for a Binding Site Barrier. Cancer Res. 1992; 52:5144-53.
12. Weinstein JN, van Osdol W. The macroscopic and microscopic pharmacology of monoclonal antibodies. Int J Immunopharmacol. 1992; 14:457-63.
13. Weinstein JN, van Osdol W. Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier". Cancer Res. 1992; 52:2747-2751.
14. Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992; 52:5144-53.
15. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011; 17:1685-91.
16. Carcinoma I-RH, Kreitman BRJ, Bailon P, Chaudhary VK, Fitzgerald DJP, Pastan I. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood. 1994; 83:426-34.
17. Tumors I-R, Webber KO, Kreitman RJ, Pastan I, Webber K. Rapid and Specific Uptake of Anti-Tac Disulfide-stabilized Fv by Rapid and Specific Uptake of Anti-Tac Disuffide-stabiized Fv by Interleukin-2 Receptor- bearing Tumors. Cancer Res. 1995; 55:318-23.
18. Barrett T, Koyama Y, Hama Y, Ravizzini G, Shin IS, Jang B-S, et al. In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res. 2007; 13:6639-48.
19. Mitsunaga M, Nakajima T, Sano K, Choyke PL, Kobayashi H. Near Infrared Theranostic Photoimmunotherapy (PIT): Repeated Exposure of Light Enhances the Effect of Immunoconjugate. Bioconjug Chem. 2012; 23:604-9.
20. Krupp MN, Connolly DT, Lane MD. Synthesis, turnover, and down-regulation of epidermal growth factor receptors in human A431 epidermoid carcinoma cells and skin fibroblasts. J Biol Chem. 1982; 257:11489-96.
21. Lopez JG, Chew J, Thompson HW, Malrer JS. EGF Cell Surface Receptor Quantitaiion on Ocular Cells by an Immunocytochemical Flow Cyfometry Technique. Invest Ophthalmol Vis Sci. 1992; 33:2053-62.
22. Yu JS, Chen HC, Yang SD. Reversible tyrosine phosphorylation/ dephosphorylation of proline-directed protein kinase FA/glycogen synthase kinase-3alpha in A431 cells. J Cell Physiol. 1997; 171:95-103.
23. Koyama Y, Barrett T, Hama Y, Ravizzini G, Choyke PL, Kobayashi H. In vivo molecular imaging to diagnose and subtype tumors through receptor- targeted optically labeled monoclonal antibodies. Neoplasia. 2007; 9:1021-9.
24. Topp EM, Kitos PA, Vijaykumar V, DeSilva BS, Hendrickson TL. Antibody transport in cultured tumor cell layers. J Control Release. 1998; 53:15-23.
25. Fazio F, Paganelli G. Antibody-guided scintigraphy: targeting of the "magic bullet". Eur J Nucl Med. 1993; 20:1138-40.
26. Kimura H, Lee C, Hayashi K, et al. UV light killing efficacy of fluorescent protein-expressing cancer cells in vitro and in vivo. J Cell Biochem. 2010; 110:1439-46.
27. Tsai M, Aki R, Amoh Y, et al. GFP-fluorescence-guided UVC irradiation inhibits melanoma growth and angiogenesis in nude mice. Anticancer Res. 2010; 30:3291-4.
28. Momiyama M, Suetsugu A, Kimura H, et al. Fluorescent proteins enhance UVC PDT of cancer cells. Anticancer Res. 2012; 32:4327-30.
29. Momiyama M, Suetsugu A, Kimura H, et al. Imaging the efficacy of UVC irradiation on superficial brain tumors and metastasis in live mice at the subcellular level. J Cell Biochem. 2013; 114:428-34.